Heart patients may get kidney protection from common diabetes pills
NCT ID NCT06491953
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looks at whether SGLT-2 inhibitors, a type of diabetes medication, can prevent kidney damage from contrast dye used during heart procedures like angioplasty. Researchers will follow 3,600 adults with acute coronary syndrome who are undergoing invasive treatment. The goal is to see if these drugs reduce the risk of acute kidney injury after the procedure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SGLT-2 inhibitors (a class of diabetes drugs that help protect the kidneys and heart)
What this could lead to
If successful, this could show that SGLT-2 inhibitors help prevent kidney injury caused by contrast dye in heart patients, offering a new protective use for these drugs.
What could go wrong
This is an observational study, not a randomized trial, so results may be less definitive. Early use of SGLT-2 inhibitors can temporarily reduce kidney function, which might increase risk in some patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE CORONARY SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
General Hospital of Northern Theater Command
Shenyang, Liaoning, China